AMNIOTIC FLUID INDEX TRIAL

The eligible mothers were included in the study after explaining them about the study objectives, methods, its benefits and potential disadvantages all the participants signed the written consent forms. Mothers with confounding factors such as post-term pregnancy, hyperthyroidism, diabetes, hypertension, heart disease, liver disease, kidney disease and amniorrhexis were excluded from the study. The inclusion criteria were a singleton pregnancy, gestational age of at least 35 weeks (based on the last menstrual period and confirmed by the results of ultrasound or determined through early pregnancy sonography), healthy fetal membranes and no evidence of fetal distress in nonstress test, structural abnormalities and fetal distress. All the pregnant women diagnosed with oligohydramnios defined as AFI ≤ 5 cm who presented to IRAN Hospital in Iranshahr were investigated in terms of eligibility for the study.

AMNIOTIC FLUID INDEX TRIAL

This double-blind randomized clinical trial study was performed in IRAN Hospital of Iranshahr in 2016–2018. The current clinical trial was conducted in 2016–2018 after receiving the approval of the Ethics Committee of the Iranshahr University of Medical Sciences with the aim to determine the effect of maternal intravenous hydration on amniotic fluid index in oligohydramnios. In addition, maternal intravenous hydration in oligohydramnios has never been studied in Iranshahr, Iran, a tropical city with a hot and dry climate. To look upon this controversy, the aim of the present study to appreciate the effect of I/V hydration upon amniotic fluid volume.

There is a lack of trials which have reported maternal hydration with intravenous infusions (infusion of 3 liters of an isotonic Ringer’s lactate solution within 24 h) in oligohydramnios. The effects of oral and infusion fluid therapies on AFI have been differently reported in literature. Treatment of oligohydramnios includes hospitalization, specialist consultation, bed rest, oral rehydration and intravenous (I/v) hydration. ĭespite the application of amnioinfusion in managing pregnant women with oligohydramnios, this method suffers certain limitations, including its exclusive application during labor, requiring fixed catheters and constant monitoring and its potential risks as a typical invasive procedure. Umber also found fluid therapy not to be as effective as maternal oral hydration therapy in increasing AFI. According to Patrelli et al., maternal oral hydration significantly increases Amniotic fluid Index (AFI) in women with a normal AFI. The appropriate management of Isolated term oligohydramnios (ITO) is controversial. Reduced uteroplacental perfusion can cause oligohydramnios by decreasing fetal renal blood flow and urine output. Amniotic fluid volume may significantly fluctuate between different gestational ages. Significant relationships of oligohydramnios, which occurs in 1–2% of pregnancies, with abnormal pregnancy outcomes such as intrauterine growth retardation (IUGR), fetal anomalies, umbilical cord compression, fetal distress, preterm childbirth, meconium-stained amniotic fluid, perinatal mortality and cesarean section necessitate the measurement of amniotic fluid volume in many prenatal fetal health assessments. The results of the present study suggested that maternal intravenous hydration significantly increases AFI in women with oligohydramnios.Īssessing amniotic fluid determines an important dimension of fetal health. Resultįorty-eight hours after completing fluid therapy, statistically significant differences were observed in the mean AFI in the intervention group (4.06 ± 0.33) and the control group (3.61 ± 0.35) (P < 0.0001) and also between the intervention group (0.532 ± 0.45) and the controls (−0.036 ± 0.18) (P < 0.0001). This study was performed aimed to assess the effect of maternal intravenous hydration on amniotic fluid index in oligohydramnios.

The appropriate management of isolated term oligohydramnios (ITO) is controversial. Significant relationships of oligohydramnios, which occurs in 1–2% of pregnancies, with abnormal pregnancy outcomes such as intrauterine growth retardation (IUGR), fetal anomalies, umbilical cord compression, fetal distress, preterm childbirth, meconium-stained amniotic fluid, perinatal mortality and cesarean section necessitate the measurement of amniotic fluid volume in many prenatal fetal health assessments.Īmniotic fluid volume may significantly fluctuate between different gestational ages. Assessing amniotic fluid determines an important dimension of fetal health.

Amniotic fluid index